Semaglutide is the foundational synthetic GLP-1 analogue and the first once-weekly GLP-1 receptor agonist to demonstrate both significant glycemic control and sustained weight reduction in research. As a long-acting GLP-1 analogue with a C18 fatty diacid chain and 94% homology to human GLP-1, it resists DPP-4 degradation with a half-life of ∼7 days. It is the gold-standard reference compound for all subsequent GLP-1 research including Tirzepatide and Retatrutide. This compound is designed for Type 2 Diabetes models with BMI 30+, metabolic syndrome research, protocols focused on appetite control and postprandial glucose spikes, and cardiovascular metabolic health studies.
Semaglutide controls metabolism through three validated organ pathways. 1. Pancreas | β-Cells → Insulin Secretion: Binds to GLP-1 receptors on β-cells, ↑cAMP → ↑insulin secretion (glucose-dependent), insulin released into bloodstream, ↓glucagon secretion from α-cells → reduces glucagon → lowers hepatic glucose output. Result: Lowers blood glucose levels. 2. Brain | Hypothalamus → Appetite Suppression: Activates GLP-1 receptors in hypothalamus (ARC/PVN appetite center), ↓hunger signaling → ↑satiety signaling, promotes feeling of fullness/satiety, modulates reward pathway → ↓food intake & cravings. Result: Reduced appetite & food consumption. 3. Stomach | Gastric Motility → Delayed Gastric Emptying: Acts on GLP-1 receptors in stomach & vagal nerve, ↓gastric motility → slower gastric emptying, food remains in stomach longer, ↑distension signal → prolonged fullness, slows nutrient absorption into intestine. Result: Promotes satiety & reduces postprandial glucose spike. Overall Effects: ↓Blood Glucose (improved glycemic control), ↓Body Weight (reduced appetite + lower caloric intake, average ∼14.9% weight loss in research), ↓Cardiovascular Risk (improved metabolic health). Semaglutide mimics natural GLP-1 hormone, glucose-dependent action minimizes hypoglycemia risk.
Our Semaglutide lineup is supplied as high-purity lyophilized powder (>99% HPLC) with COA. For dose-escalation and research protocols, we offer Semaglutide 2mg (starter / low-dose), Semaglutide 5mg (standard - most requested), Semaglutide 10mg (high-dose) and Semaglutide 15mg (value size for long-term protocols). Compared to Tirzepatide and Retatrutide, Semaglutide is the single GLP-1 mechanism, providing the cleanest model for GLP-1R-specific studies without GIP or glucagon confounding. Stable for 24 months at -20°C, 30 days reconstituted at 2-8°C. Commonly researched alongside B12 5ml for energy, MOTS-c 5mg for metabolic support, and BPC-157 for gut protection. For Research Use Only, not for human consumption.